BioCryst Pharmaceuticals, Inc.
BCRX
$8.80
$0.222.56%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -393.60% | 1,805.92% | 153.67% | 15,790.63% | 100.12% |
| Total Depreciation and Amortization | 24.24% | -56.74% | 500.00% | -0.60% | -58.47% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,679.53% | 45.92% | -16.08% | -0.58% | 4.96% |
| Change in Net Operating Assets | -1,789.21% | 408.54% | -157.64% | 103.83% | -448.34% |
| Cash from Operations | -121.16% | 601.42% | 0.78% | 250.10% | -427.85% |
| Capital Expenditure | 49.75% | 40.33% | -650.84% | -25.17% | 78.81% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 389.18% | -632.53% | -50.98% | 7.59% | 47.46% |
| Cash from Investing | -221.78% | -715.15% | -53.40% | 7.50% | 52.24% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 99.58% | -223.95% | 20.19% | -14,677.13% | -44.94% |
| Issuance of Common Stock | 2,769.41% | -74.51% | -22.22% | 43.16% | -- |
| Repurchase of Common Stock | 80.22% | -855.73% | 27.48% | 35.90% | 63.14% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 68.05% | -- | -- | -- | -- |
| Cash from Financing | 289.28% | -270.59% | 20.18% | -14,029.30% | 113.16% |
| Foreign Exchange rate Adjustments | 0.00% | 84.62% | -134.44% | 201.33% | 134.59% |
| Miscellaneous Cash Flow Adjustments | -- | 6,707.34% | 101.45% | -- | -- |
| Net Change in Cash | 1,453.81% | 236.50% | 77.19% | -3,138.71% | -92.31% |